ARGATROBAN Drug Interactions
Also known as: Argatroban
Argatroban is a medication that helps prevent and treat blood clots, especially in adults who have a condition called heparin-induced thrombocytopenia (HIT). It works by blocking a substance in the blood called thrombin, which is essential for clot formation, thereby keeping the blood from clotting too much. This also makes it useful as a blood thinner during certain heart procedures (like PCI) for patients with HIT.ARGATROBAN has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with argatroban significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase (COX) enzymes, leading to decreased prostaglandin synthesis and impaired platelet aggregation. Argatroban is a direct thrombin inhibitor, which directly prevents fibrin clot formation. The concurrent use of both agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly elevated risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., ulcers, melena, hematemesis), intracranial hemorrhage, hematuria, or excessive bleeding from minor injuries. The risk of serious GI bleeding with NSAIDs and anticoagulants can be several-fold higher compared to either agent alone. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is unavoidable, extreme caution, close monitoring for signs of bleeding, and the lowest effective doses for the shortest duration are essential. Consider alternative pain management strategies that do not involve NSAIDs, or alternative anticoagulants if appropriate. Monitor hemoglobin, hematocrit, and coagulation parameters closely.
Combining Etodolac with Argatroban significantly increases your risk of serious bleeding, including internal bleeding. Your doctor will likely avoid this combination.
Mechanism
Etodolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Argatroban is a direct thrombin inhibitor that prevents fibrin formation and platelet aggregation. The combination leads to additive antiplatelet and anticoagulant effects, increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. Patients may experience symptoms such as black, tarry stools, blood in urine, unusual bruising, or prolonged bleeding from minor cuts. The risk of major bleeding can be several-fold higher compared to monotherapy. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or use the lowest effective dose for the shortest duration possible, with close monitoring for bleeding. Monitor complete blood count, coagulation parameters, and clinical signs of bleeding frequently. Proton pump inhibitors may be considered to reduce GI bleeding risk if an NSAID is unavoidable.
Combining aspirin with argatroban significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided unless the benefits clearly outweigh the very high risks.
Mechanism
Aspirin inhibits platelet aggregation irreversibly by blocking cyclooxygenase-1 (COX-1), reducing thromboxane A2 production. Argatroban is a direct thrombin inhibitor, preventing thrombin's procoagulant effects. The concurrent use of an antiplatelet agent and an anticoagulant leads to additive impairment of hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This can manifest as easy bruising, nosebleeds, gum bleeding, or more severe events like gastrointestinal bleeding, intracranial hemorrhage, or hematuria. The risk of major bleeding is significantly elevated compared to either drug alone. This combination should be avoided if possible. If concomitant use is deemed absolutely necessary due to critical indications for both drugs, patients require extremely close monitoring for signs of bleeding. Consider alternative therapies or dose adjustments under strict medical supervision. Patient education on bleeding symptoms is crucial.
Taking ibuprofen with argatroban significantly increases your risk of bleeding, including serious internal bleeding. You should avoid this combination unless specifically directed by your doctor.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Argatroban is a direct thrombin inhibitor, which prevents clot formation. The combined antiplatelet effect of ibuprofen and the anticoagulant effect of argatroban lead to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other serious hemorrhagic events. Patients may experience symptoms such as bruising, nosebleeds, blood in urine or stool, or severe abdominal pain. The risk of major bleeding is substantially elevated compared to using either drug alone. This combination should generally be avoided due to the high risk of bleeding. If an analgesic is required, acetaminophen is a safer alternative. If NSAID use is absolutely essential, close monitoring for signs of bleeding is critical, and the lowest effective dose for the shortest duration should be used. Consider alternative anticoagulant strategies if possible.
Combining indomethacin with argatroban significantly increases your risk of serious bleeding, including stomach bleeding. This combination should generally be avoided.
Mechanism
Indomethacin, a non-selective NSAID, inhibits cyclooxygenase (COX-1 and COX-2) enzymes, leading to reduced prostaglandin synthesis. This impairs platelet aggregation and damages the gastrointestinal mucosal barrier. Argatroban is a direct thrombin inhibitor, which directly interferes with the coagulation cascade, prolonging clotting times. The combined antiplatelet effect of indomethacin and the anticoagulant effect of argatroban lead to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also bleeding at other sites like the brain or urinary tract. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. The risk of serious GI bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is unavoidable, close monitoring for signs and symptoms of bleeding is essential, along with frequent checks of coagulation parameters (e.g., aPTT, INR, ACT, depending on argatroban use). Consider alternative pain management strategies that do not involve NSAIDs, or use a gastroprotective agent (e.g., PPI) if an NSAID is absolutely necessary and the bleeding risk is deemed acceptable by the prescriber.
Combining celecoxib with argatroban significantly increases your risk of bleeding, including serious and life-threatening bleeding episodes. This combination should generally be avoided.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation, although its COX-2 selectivity means a lesser effect on platelets than non-selective NSAIDs. Argatroban is a direct thrombin inhibitor that directly interferes with the coagulation cascade. The concurrent use leads to additive antihemostatic effects, increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This can manifest as gastrointestinal bleeding (e.g., melena, hematemesis), intracranial hemorrhage, hematuria, epistaxis, or excessive bruising. The risk of major bleeding is significantly elevated compared to either drug alone. This combination should generally be avoided due to the high risk of severe bleeding. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and frequent assessment of coagulation parameters (e.g., aPTT for argatroban). Consider alternative pain management strategies that do not involve NSAIDs. If an NSAID is unavoidable, consider topical formulations with lower systemic absorption, though even these carry some risk.
Combining piroxicam with argatroban significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely avoid this combination.
Mechanism
Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Argatroban is a direct thrombin inhibitor that prevents clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or even fatal. Other bleeding sites include intracranial, genitourinary, and soft tissue. The risk of major bleeding with NSAID plus anticoagulant therapy can be several-fold higher compared to anticoagulant monotherapy. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or use a COX-2 selective NSAID with extreme caution and a proton pump inhibitor for gastroprotection, while closely monitoring for signs of bleeding. Frequent monitoring of bleeding parameters and clinical signs is crucial if co-administration cannot be avoided.
Combining meloxicam with argatroban significantly increases your risk of serious bleeding, including stomach bleeding. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet function. Argatroban is a direct thrombin inhibitor that prevents fibrin formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, severely impairing hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also hemorrhage at other sites. This can manifest as blood in stool, vomiting blood, easy bruising, or prolonged bleeding from minor cuts. The risk of major bleeding can be several-fold higher compared to either drug alone. This combination should be avoided if possible. If concomitant use is absolutely necessary, patients must be closely monitored for signs and symptoms of bleeding, and argatroban dosage may need adjustment with frequent coagulation monitoring (aPTT). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If an NSAID is unavoidable, a COX-2 selective agent might be considered, but still carries significant risk.
Combining diclofenac with argatroban significantly increases your risk of bleeding, particularly from the stomach or intestines. This combination should generally be avoided.
Mechanism
Diclofenac, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Argatroban is a direct thrombin inhibitor, directly preventing clot formation. The combined effect of impaired platelet function and direct anticoagulation leads to a substantial increase in bleeding risk.
Clinical Management
Patients are at a significantly increased risk for serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding. The risk of GI bleeding can be 3-15 times higher when NSAIDs are co-administered with anticoagulants compared to anticoagulants alone. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, patients must be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be considered for GI protection. Alternative pain management strategies that do not involve NSAIDs should be explored.
Combining ketorolac with argatroban significantly increases your risk of serious bleeding, including bleeding in the stomach or intestines. This combination should generally be avoided.
Mechanism
Ketorolac, a non-selective NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby impairing platelet aggregation. Argatroban is a direct thrombin inhibitor, preventing fibrin formation and thrombus propagation. The concurrent use results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding. The risk of gastrointestinal bleeding alone can be several-fold higher compared to either drug alone, potentially leading to anemia, hypovolemic shock, or death. This combination should generally be avoided due to the high risk of severe bleeding. If concurrent use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., melena, hematemesis, epistaxis, bruising, changes in vital signs, decreasing hemoglobin) and frequent coagulation parameter checks. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids.
For complete prescribing information:
View full ARGATROBAN monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.